Back to today’s briefing

Story perspectives

Teen Battles Obesity: Wegovy Use Soars 594%

2/27/2025

44 6

Summary

Story summary

Fifteen-year-old Jenny Arrellin, battling polycystic ovary syndrome, took a brave step by participating in a Wegovy study aimed at tackling obesity and lowering her diabetes risk. The medication transformed her appetite and food choices. Remarkably, from 2020 to 2023, the use of GLP-1 drugs among teens skyrocketed by 594%, with Wegovy now available for those aged 12 and up.

1 of 1

Story summary

Fifteen-year-old Jenny Arrellin, battling polycystic ovary syndrome, took a brave step by participating in a Wegovy study aimed at tackling obesity and lowering her diabetes risk. The medication transformed her appetite and food choices. Remarkably, from 2020 to 2023, the use of GLP-1 drugs among teens skyrocketed by 594%, with Wegovy now available for those aged 12 and up.